Loading clinical trials...

EMDR Integrative Group Protocol and Individual Treatment for Patients With Cancer: A Pilot Study | Clinical Trials | Clareo Health

RECRUITINGNA

EMDR Integrative Group Protocol and Individual Treatment for Patients With Cancer: A Pilot Study

Combination of the EMDR Integrative Group Protocol and Individual EMDR Treatment in Patients With Advanced Thyroid Cancer: A Pilot Study

NCT07447089•Università Cattolica di Milano

View on ClinicalTrials.gov

Summary

The main aim of the present process-outcome study is to evaluate the feasibility and the effects of an EMDR-IGTP-OTS group intervention on a sample of people with cancer, by using a process-outcome study design, with repeated measures.

Detailed Description

The diagnosis of cancer represents a potentially life-threatening event that can be considered a unique traumatic stressor. A cancer diagnosis can disrupt a person's life, affecting emotions, cognition, and physical pain impacting the individual sense of identity. Findings from the literature suggest that EMDR can be a valid treatment in the processing of cancer-related traumatic events. With this proposal, the investigators aim to evaluate the feasibility and the effects of a combined EMDR Integrative Group Treatment Protocol and an optional EMDR individual protocol for people with cancer.

Eligibility

Age

18 - 100 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•cancer diagnosis
•PTSD (IES-R \> 32)

Exclusion Criteria

•receiving specialized trauma therapy
•receiving current psychiatric pharmacological treatment, unless the dosage has been stable for at least 2 months prior to enrollment

Locations (1)

Università Cattolica del Sacro Cuore

Milan, Italy

Key Dates

Start Date

December 5, 2025

Primary Completion Date

October 1, 2026

Completion Date

December 5, 2026

Last Updated

March 4, 2026

Enrollment

ESTIMATED participants

Conditions

Thyroid NeoplasmsNeoplasmPost-traumatic Stress Disorder (PTSD)Psychological Distress

Interventions

EMDR-IGTP-OTS

BEHAVIORAL

Contacts

Cesare Cavalera

CONTACT

+393409373408 cesarem.cavalera@unicatt.it

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

NCT05053971

Advanced Malignant Solid NeoplasmLocally Advanced Pancreatic Carcinoma+7 more

View study

RECRUITINGPHASE2

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

NCT06126276

Malignant Female Reproductive System NeoplasmMalignant Solid Neoplasm+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 4, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

EMDR Integrative Group Protocol and Individual Treatment for Patients With Cancer: A Pilot Study

Inclusion Criteria

Exclusion Criteria

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)